Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company focused on developing novel serotonergic agonists (NSAs), has announced that its Chief Medical Officer, Amir Inamdar, will participate in a fireside chat at the H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference. The conference is scheduled for June 15-16, 2026, and the fireside chat will be available on demand starting June 15 at 7:00 a.m. EDT.
This participation underscores Helus Pharma's commitment to advancing its pipeline of NSAs, which are synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. The company's proprietary NSAs aim to address the large unmet need for individuals suffering from depression, anxiety, and other mental health conditions. Helus Pharma currently has two lead candidates in clinical development: HLP003, a proprietary NSA in Phase 3 clinical development for the adjunctive treatment of major depressive disorder, which has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration; and HLP004, another proprietary NSA in Phase 2 for generalized anxiety disorder. Additionally, the company maintains an extensive research portfolio of investigational NSAs.
The H.C. Wainwright Neuro Perspectives Conference provides a platform for industry leaders to discuss the latest advancements in neuroscience and mental health treatments. Inamdar's participation highlights Helus Pharma's progress and its potential impact on the treatment landscape for mental health conditions. The company aims to improve patient outcomes through the introduction of NSAs that provide durable improvements in mental health, as evidenced by its class-leading data.
Helus Pharma, the commercial operating name of Cybin Inc., founded in 2019, operates in Canada, the United States, the United Kingdom, and Ireland. For more information about the company and its developments, visit www.helus.com. The full press release regarding this announcement is available at https://ibn.fm/KsnJW.
The implications of this announcement are significant for the mental health treatment industry. Helus Pharma's focus on NSAs represents a novel approach to addressing conditions like major depressive disorder and generalized anxiety disorder, which affect millions worldwide. The Breakthrough Therapy Designation for HLP003 underscores the potential of this therapy to offer meaningful improvements over existing treatments. As the company progresses through clinical trials, successful outcomes could lead to new, more effective options for patients and reshape the standard of care.
Investors and stakeholders in the pharmaceutical and biotechnology sectors will be closely watching Helus Pharma's developments. The company's participation in the H.C. Wainwright conference provides an opportunity for the investment community to gain insights into its strategy and pipeline progress. For ongoing updates, the company's newsroom is available at https://ibn.fm/HELP.
